Protocol Ledger

NCT07501702 · Phase II · ACTIVE NOT RECRUITING

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

Interventional Phase II clinical trial protocol NCT07501702 sponsored by Vertex Pharmaceuticals in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-13 Enrollment: 34 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07501702
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)34 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07501702
Protocol FieldVerified Registry Value
NCT IdentifierNCT07501702
Consolidated Lead SponsorVertex Pharmaceuticals
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment34 participants (ACTUAL)
Registered Start Date2026-05-13
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI